Jesse Cleaver
General Practice · Greensboro, NCNPI 1740824614
Payments from drug & device makers
Across 159 payments — averaging $16.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$481
- AstraZeneca$238
- Boehringer Ingelheim$223
- Bayer$167
- E.r. Squibb & Sons, L.L.C.$152
- Heartflow, Inc.$133
- plus $1K from 20 others
What the payments were for
- Food & beverage$2,573100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 31 | $481 |
| AstraZeneca | 17 | $238 |
| Boehringer Ingelheim | 15 | $223 |
| Bayer | 11 | $167 |
| E.r. Squibb & Sons, L.L.C. | 11 | $152 |
| Heartflow, Inc. | 4 | $133 |
| Sanofi-aventis U.S. LLC | 8 | $124 |
| Cvrx, Inc. | 7 | $115 |
| Merck | 8 | $111 |
| Kiniksa Pharmaceuticals International, PLC | 6 | $106 |
| Esperion Therapeutics, Inc. | 5 | $92 |
| Novartis | 5 | $88 |
| Pfizer | 4 | $80 |
| Johnson & Johnson | 5 | $69 |
| Novo Nordisk | 4 | $61 |
| Alnylam Pharmaceuticals Inc. | 3 | $58 |
| Boston Scientific | 2 | $52 |
| Lexicon Pharmaceuticals, Inc. | 2 | $41 |
| Daiichi Sankyo Inc. | 2 | $40 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $39 |
| Kowa Pharmaceuticals America, Inc. | 2 | $25 |
| Biohaven Pharmaceuticals, Inc. | 1 | $23 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $14 |
| Amryt Pharma Holdings Ltd | 1 | $14 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $10 |
How this compares
$2,573 in reported general payments places this provider in the 90th percentile of 2,924 general practice providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 94 | $80,382 |
| EntrestoSacubitril/Valsartan | 54 | $55,260 |
| XareltoRivaroxaban | 22 | $24,505 |
| Repatha SureclickEvolocumab | 15 | $14,962 |
| JardianceEmpagliflozin | 14 | $10,722 |
| Clonidine | 12 | $1,884 |
| Rosuvastatin Calcium | 69 | $1,128 |
| Metoprolol Succinate | 81 | $1,128 |
| Atorvastatin Calcium | 66 | $960 |
| Valsartan | 12 | $694 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 30 | $679 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 45 | $614 |
| Torsemide | 26 | $589 |
| Nitroglycerin | 49 | $570 |
| Amlodipine Besylate | 84 | $541 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $80 | $80,38294 claims |
| NovartisEntresto | $88 | $55,26054 claims |
| Johnson & JohnsonXarelto | $69 | $24,50522 claims |
| Boehringer IngelheimJardiance | $223 | $10,72214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,924 general practice providers in North Carolina.
Other general practice in Greensboro
- Andrew KellyGreensboro$115K
- Mark HymanGreensboro$95K
- Jerry ReevesGreensboro$72K
- Graham FarlessGreensboro$56K
- Rosemary BaghdassarianGreensboro$11K
- Elise NewsomeGreensboro$9K
- Guy RibandoGreensboro$8K
- Matthew MillerCharlotte$937K
- James BarberDurham$768K
- Robert LoweCharlotte$615K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.